By Dr. Rajiv Lochan J, Lead & Senior Consultant – Surgical Gastroenterology, HPB Surgery & Liver Transplantation, KIMS Hospitals, Bengaluru
For a long time, a diagnosis of hepatitis B or C felt like a life sentence. Chronic infection, years of monitoring, the shadow of cirrhosis and liver cancer hanging over every follow-up appointment. That picture has changed substantially, and the change has been more dramatic for some forms of hepatitis than for others. Understanding where treatment currently stands is useful both for people living with hepatitis and for those who know someone who is.
Hepatitis A: Always Been Curable
Hepatitis A has never required antiviral treatment in the way that B and C do. It is an acute infection transmitted through contaminated food and water that the immune system clears on its own in the vast majority of cases. Supportive care, rest, and hydration are the management, and chronic hepatitis A does not exist. Vaccination prevents it entirely, and this is the most important message about hepatitis A: it is wholly preventable.
Hepatitis C: Now Effectively Curable
The most dramatic shift in hepatitis treatment over the past decade has been in hepatitis C. What was once managed with a difficult combination of interferon injections and ribavirin, producing significant side effects and cure rates that varied considerably by viral genotype, has been transformed by the development of directly acting antiviral agents.
These oral medications, taken for eight to twelve weeks depending on the genotype and stage of liver disease, now achieve cure, defined as undetectable viral load six months after completing treatment, in over 95% of patients. The side effect profile is minimal compared to the old interferon-based regimens. Patients who were previously told they were poor candidates for treatment due to advanced liver disease or other health conditions can now often be treated successfully.
The implications of this are significant. Hepatitis C, which causes an estimated 70% of hepatocellular carcinoma cases in some populations, is now a curable infection. The barrier is no longer the medicine. It is diagnosis, because a substantial proportion of people dealing with chronic hepatitis C are unaware they have it.
Hepatitis B: Manageable but Not Yet Curable
Hepatitis B tells a different story. The virus seeps into the DNA of liver cells in a way that current antivirals cannot fully eliminate. What modern treatment achieves is sustained viral suppression, keeping the viral load undetectable in the blood and preventing the liver damage that active viral replication causes.
Patients on antiviral therapy for hepatitis B:
● Significantly reduce their risk of cirrhosis and liver cancer
● Can expect near-normal life expectancy with consistent treatment
● Require long-term or lifelong treatment in most cases
A functional cure, defined as loss of the hepatitis B surface antigen from the blood, is achieved in a small proportion of patients on treatment. Research into new drug classes that target different stages of the viral life cycle, including capsid assembly inhibitors and RNA interference therapies, is actively ongoing and gives genuine grounds for optimism that a more complete cure may be achievable within the next decade.
What This Means Practically
● Anyone who suspects hepatitis exposure should be tested
● A hepatitis C diagnosis today is not the same as it was ten years ago
● Hepatitis B requires lifelong monitoring even when treated
● Vaccination against hepatitis A and B remains the most cost-effective intervention available
Conclusion
The landscape of hepatitis treatment has changed more in the last ten years than in the several decades before. For hepatitis C, cure is now the expectation rather than the exception. For hepatitis B, effective control that protects the liver and extends life is available to almost everyone who needs it. The biggest remaining challenge is getting people tested so that treatment can begin.
